Author: admin

© Reuters. SIOUX FALLS, S.D. – SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company, announced today that it has successfully regained compliance with Nasdaq’s minimum bid…